Human response against NP-4, a mouse antibody to carcinoembryonic antigen: human anti-idiotype antibodies mimic an epitope on the tumor antigen.

Losman, Michele J.; Hansen, Hans J.; Sharkey, Robert M.; Goldenberg, David M.; Monestier, Marc

doi:10.1073/pnas.88.8.3421

Cited by 13 publications

(6 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In accordance with Jerne theory, it has been reported that humoral immune responses characterized by anti-Id antibody production can be elicited in cancer patients following mAb injection for therapeutic or diagnosis purposes [27,33,[57][58][59][60][61][62]. In some cases, the production of anti-Id antibodies even correlated with patient clinical responses.…”

Section: Fcγr-dependent Mechanisms Of Actionmentioning

confidence: 70%

Modulation of tumor immunity by therapeutic monoclonal antibodies

Abès

Teillaud

2011

Cancer Metastasis Rev

View full text Add to dashboard Cite

The surveillance of tumors by the immune system of cancer patients and its impact on disease progression and patient survival have been largely documented over the last years. In parallel, the use of therapeutic monoclonal antibodies (mAbs) in oncology has gained a widespread recognition as it has made it possible to increase patient survival and to ameliorate the quality of life in a number of cancers. However, the clinical responses observed following mAb treatment remain largely heterogeneous and their duration is still highly unpredictable. Recently, the concept that the injection of therapeutic antibodies not only triggers early anti-tumor events such as receptor blockade, cytostasis, apoptosis, complement-dependent cytotoxicity and/or antibody-dependent cytotoxicity but also allows the host immune system to fight tumor cells through the development of a long-lasting adaptive immunity has emerged. In the present review, we will examine the arguments that support this concept by detailing the cellular and molecular events likely to underlie the induction of an efficient anti-tumor adaptive immune response by mAbs. We will also discuss the consequences of this induction on the way therapeutic antibodies can be used and inserted in a more global immunotherapeutic approach aiming at strengthening the adaptive anti-tumor immune response developed by cancer patients.

show abstract

Section: Fcγr-dependent Mechanisms Of Actionmentioning

confidence: 70%

Modulation of tumor immunity by therapeutic monoclonal antibodies

Abès

Teillaud

2011

Cancer Metastasis Rev

View full text Add to dashboard Cite

show abstract

“…Many anti-idiotypic antibodies have been described to monoclonal antibodies that recognize CEA [3,8,13,30,37,51 ]. The majority of these studies describe Ab2 species that induce Ab3 humoral immune responses specific for CEA [3,8,13,30,51] characterized by Western blot [13], immunoprecipitation [3] and immunoassays [3,8,13,30,51 ], as well as by immunohistochemical staining of colon carcinoma tissue sections [3].…”

Section: Discussionmentioning

confidence: 99%

“…The majority of these studies describe Ab2 species that induce Ab3 humoral immune responses specific for CEA [3,8,13,30,51] characterized by Western blot [13], immunoprecipitation [3] and immunoassays [3,8,13,30,51 ], as well as by immunohistochemical staining of colon carcinoma tissue sections [3]. One study has reported an Ab2 to an anti-CEA mAb that can induce a cell-mediated immune response [8].…”

Section: Discussionmentioning

confidence: 99%

“…Two panels of mouse mAb recognizing the two distinct human tumor-associated antigens, TAG-72 and CEA, were used. One panel of anti-TAG-72 mAb (B72.3, CC11, 15,29,30,40,46,49,83,92, and 112) recognized multiple epitopes of the TAG-72 molecule [27]. The panel of anti-CEA mAb (COL-l, 4, 6, 7, and 11), was generated as previously described, and recognized different epitopes of CEA [26].…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Induction of delayed-type hypersensitivity responses by monoclonal anti-idiotypic antibodies to tumor cells expressing carcinoembryonic antigen and tumor-associated glycoprotein-72

Irvine

Schlom

1993

Cancer Immunol Immunother

View full text Add to dashboard Cite

The use of anti-idiotypic antibodies as immunogens represents one potential approach to active specific immunotherapy of cancer. Two panels of syngeneic monoclonal anti-idiotypic antibodies were generated. One panel was directed against mAb CC49 and the other to mAb COL-1. mAb CC49 recognizes the pancarcinoma antigen (Ag), tumor-associated glycoprotein-72 (TAG-72), and mAb COL-1 recognizes carcinoembryonic antigen (CEA). Seven anti-idiotypic (AI) antibodies (Ab2) designated AI49-1-7 were generated that recognize the variable region of mAb CC49. These mAb were shown to inhibit the interaction of mAb CC49 (Ab1) with TAG-72 (Ag). Five anti-idiotypic antibodies designated CAI-1-5 were also generated to the anti-CEA mAb, COL-1 (Ab1). These Ab2 were shown to inhibit the interaction between COL-1 (Ab1) and CEA (Ag). Immunization of mice, rats, and rabbits with Ab2 directed against CC49 or COL-1 could not elicit specific Ab3 humoral immune responses, i.e., antibody selectively reactive with their respective target antigens. However, immunization of mice with the CC49 anti-idiotypic antibody (Ab2), designated AI49-3, could induce a delayed-type hypersensitivity response (DTH) specific for tumor cells that express TAG-72. Similarly, immunization of mice with an anti-idiotypic antibody directed against COL-1, designated CAI-1, could induce specific DTH cell-mediated immune responses to murine tumor cells that express human CEA on their surface. These results thus demonstrate that while some anti-idiotype mAb may not be potent immunogens in eliciting Ab3 humoral responses, they are capable of eliciting specific cellular immune responses against human carcinoma-associated antigens. This type of mAb may ultimately be useful in active immunotherapy protocols for human carcinoma.

show abstract

“…Rabbit Ab3 was purified using an adaptation of the affinity chromatography protocol described previously (Losman et a/., 1990(Losman et a/., , 1991. Briefly, Ab2-immunized rabbit serum was adsorbed onto a column of Ab2 coupled to an Affi-Gel matrix (Bio-Rad, Richmond, CA) and the bound antibodies were eluted with a 0.1 M glycine-HC1 buffer, pH 2.8.…”

Section: Ab2 Immunizationmentioning

confidence: 99%

Mimicry of a carcinoembryonic antigen epitope by a rat monoclonal anti‐idiotype antibody

Losman¹,

Novick²,

Goldenberg³

et al. 1994

Intl Journal of Cancer

View full text Add to dashboard Cite

Anti-idiotype antibodies (Ab2) that immunologically mimic tumor antigens are auspicious agents for the active immunization of cancer patients. We have developed W12, a rat monoclonal IgG1 Ab2 to MN-14, a murine anti-carcinoembryonic antigen (CEA) monoclonal antibody. W12 is specific for MN-14 and does not react with other isotype-matched anti-CEA monoclonal antibodies. Moreover, W12 inhibits the binding between MN-14 and CEA. Anti-CEA antibodies can be induced by immunization with W12 (but not with control rat IgG) in xenogenic animals (mice or rabbits). Immunoblotting studies indicate that the internal image determinant borne by W12 is conformational and requires the association of the heavy and light chains of the Ab2 molecule. This study indicates that W12 is a potential idiotype vaccine in patients with CEA-producing cancers.

show abstract

Human response against NP-4, a mouse antibody to carcinoembryonic antigen: human anti-idiotype antibodies mimic an epitope on the tumor antigen.

Cited by 13 publications

References 26 publications

Modulation of tumor immunity by therapeutic monoclonal antibodies

Modulation of tumor immunity by therapeutic monoclonal antibodies

Induction of delayed-type hypersensitivity responses by monoclonal anti-idiotypic antibodies to tumor cells expressing carcinoembryonic antigen and tumor-associated glycoprotein-72

Mimicry of a carcinoembryonic antigen epitope by a rat monoclonal anti‐idiotype antibody

Contact Info

Product

Resources

About